Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease

American Journal of Kidney Diseases

Volumn 39, Issue 2, 2002, Pages 426-432

  Van Wyck, David B ^a,b,c   Bailie, George ^a,b,c   Aronoff, George ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Adverse effects; Anemia; Chronic kidney disease (CKD); Ferritin; Hemodialysis (HD); Hemoglobin; Iron; Iron deficiency; Iron dextran; Iron gluconate; Iron sucrose; Transferrin saturation

Indexed keywords

ASCORBIC ACID; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BLEEDING; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DISEASE MARKER; DISEASE PREDISPOSITION; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; INFECTION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; OUTCOMES RESEARCH; TRANSFERRIN BLOOD LEVEL;

EID: 0036180672     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.30566     Document Type: Article

References (33)

1. 2000 Annual Report: ESRD Clinical Performance Measures Project
2. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998
3. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial
4. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rHuEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency
5. Laboratory diagnosis of anaemia in dialysis patients: Use of common laboratory tests
6. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO
7. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients
8. The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients
9. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
10. Role of cytokines in the response to erythropoietin in hemodialysis patients
11. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients
12. Silent infection in clotted hemodialysis access grafts
13. Iron treatment: Impact of safety issues
14. Erythropoietin and iron use in peritoneal dialysis patients: Report from the 1997 HCFA end-stage renal disease core indicators project
15. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
16. Characteristics of iron dextran utilization in man
17. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era
18. Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis
19. Iron and infection: New developments and their implications
20. Iron and infection
21. Risk factor for bacterial infections in chronic haemodialysis adult patients: A multicenter prospective survey
22. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia
23. A study of parenteral iron regimens in hemodialysis patients
24. Importance of iron supply for erythropoietin therapy
25. Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients
26. Value of methylprednisolone in prevention of the arthralgiamyalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial
27. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans
28. The safety of intravenous iron dextran in hemodialysis patients
29. Suspected iron dextran-related adverse drug events in hemodialysis patients
30. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period